L310-2509 Screening compound: N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide

L310-2509 Screening compound: N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide
L310-2509 Screening compound: N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L310-2509
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L310-2509

Molecular Formula

C22H22N4O7S (C22 H22 N4 O7 S)

Compound Name

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide

IUPAC name

N-(23-dihydro-14-benzodioxin-6-yl)-4-[(5-ethyl-124-oxadiazol-3-yl)methyl]-6-methyl-3-oxo-34-dihydro-2H-14-benzoxazine-7-sulfonamide

SMILES

CCc1nc(CN(C(COc2c3)=O)c2cc(C)c3S(Nc(cc2)cc3c2OCCO3)(=O)=O)no1

InChI

InChI=1S/C22H22N4O7S/c1-3-21-23-20(24-33-21)11-26-15-8-13(2)19(10-17(15)32-12-22(26)27)34(28,29)25-14-4-5-16-18(9-14)31-7-6-30-16/h4-5,8-10,25H,3,6-7,11-12H2,1-2H3

InChI Key

AEQOOGAQADCKKL-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27244490

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

486.51

Hydrogen Bond Acceptors Count

12.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

11

Partition Coefficient, logP

1.886

Distribution Coefficient, logD

1.819

Water Solubility, LogSw

-2.78

Polar Surface Area

113.146

Acid Dissociation Constant (pKa)

8.18

Base Dissociation Constant (pKb)

-4.44

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

31.80

L310-2509 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Anti-HIV1 Library (19540 compounds)

Antibacterial Compounds Library (13827 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Antiviral
  • Infections
  • Immune system
  • Infections
  • Immune system
  • animal

References: we are preparing a list of scientific research reports with L310-2509 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L310-2509?
Check Price and Availability of L310-2509, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L310-2509 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L310-2509
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L310-2509
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L310-2509 available by request